Posts Tagged ‘Nasdaq’

  • Nektar Begins Phase II Study of New Opioid

    Nektar Therapeutics (NASDAQ: NKTR) has enrolled the first patient in a Phase II clinical study of a new opioid analgesic that is designed to enter the brain slowly, reducing the potential for the drug to be abused or misused. The…

    Read More >
140 queries. 0.846 seconds.